[go: up one dir, main page]

Mittendorf et al., 2006 - Google Patents

Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer

Mittendorf et al., 2006

Document ID
15708344788698686813
Author
Mittendorf E
Storrer C
Shriver C
Ponniah S
Peoples G
Publication year
Publication venue
Annals of surgical oncology

External Links

Snippet

Abstract Trastuzumab, an anti-HER2/neu monoclonal antibody, is thought to promote HER2/neu receptor internalization and/or turnover. This study was designed to investigate the kinetics of trastuzumab treatment on tumor cells with varying levels of HER2/neu …
Continue reading at search.proquest.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links

Similar Documents

Publication Publication Date Title
Mittendorf et al. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer
JP7004470B2 (en) Chimeric antigen receptor targeting CD-19
Feldman et al. Adoptive cell therapy—tumor-infiltrating lymphocytes, T-cell receptors, and chimeric antigen receptors
CN110272490B (en) Targeted CTLA-4 antibody, preparation method and application thereof
Zhou et al. Breast cancer immunotherapy
US10429392B2 (en) Methods and compositions for diagnosis and treatment of cancer
CN104356225B (en) CDH3 peptides and the medicament containing CDH3 peptides
Wang et al. Immunotherapy in ovarian cancer
EP3368067B1 (en) Compositions and methods for the treatment of her2-expressing solid tumors
US20030068318A1 (en) Treatment of uterine serous papillary cancer
Miyako et al. Antitumor effect of new HER2 peptide vaccination based on B cell epitope
JP2021500336A (en) Treatment of ovarian cancer with anti-CD47 and anti-PD-L1
JP2003505696A (en) Determination of antibodies to NY-ESO-1 in cancer patients
CN109195988A (en) Methods and compositions for enhancing the efficacy of superantigen-mediated cancer immunotherapy
CN102947325B (en) Cdca5 peptides and vaccines including the same
US20210388109A1 (en) Compositions and methods regarding engineered and non-engineered gamma delta t-cells for treatment of solid tumors
JP2002538074A (en) Isolated peptides corresponding to the amino acid sequence of NY-ESO-1 and binding to MHC class I and MHC class II molecules and methods of using same
Hu et al. Overexpression of B7-H3 as an opportunity for targeted therapy in head and neck cancers
AU2012329502A1 (en) TOPK peptides and vaccines including the same
Bonino et al. Bispecific monoclonal antibody anti‐CD3 X anti‐tenascin: An immunotherapeutic agent for human glioma
EP1131426B1 (en) Mage-10 or mage-8 derived hla-a2.1-binding oligopeptides
TW202333769A (en) Antitumor agent and evaluation method thereof
CN116003627A (en) NKG2D-NKp46 cell adaptor molecules and uses thereof
AU2018308982A1 (en) Methods and compositions for the treatment of cancer
CN115304680A (en) Preparation and Application of Bispecific Cell Engager Molecules Based on Pep42